Literature DB >> 7602214

Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group.

P Jamet1, B Ji.   

Abstract

Thirty-five multibacillary (MB) leprosy patients were treated with 2 years of multidrug therapy (MDT) and followed up regularly for relapse. Relapse was defined as: a) an increase of the bacterial index (BI) by 2+ over the previous value from any single site of old lesions and b) the occurrence of definite new skin lesion(s) which demonstrated a higher BI than any pre-existing lesion. After a mean duration of 72.7 +/- 17.3 months of follow up per patient, seven relapses were diagnosed; the mean incubation period of relapse was 62.7 +/- 18.7 months. The overall relapse rate was 20.0% (or 3.3 per 100 patient-years), very significantly higher than the figures obtained from the same group of patients analyzed 2 1/2 years earlier, indicating that relapses occurred late (at least 5 +/- 2 years) after stopping MDT. Further analysis indicated that the relapse rate was closely correlated with the bacterial load of the patient, occurring far more frequently among patients with a BI of > or = 4.0 before MDT or with a BI of > or = 3.0 at the end of MDT. To avoid the alarmingly high relapse rate, it is proposed that the duration of MDT be doubled to 4 years in patients with an average BI of > or = 4.0 before MDT.

Entities:  

Mesh:

Year:  1995        PMID: 7602214

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  14 in total

1.  Another view of the therapy of leprosy.

Authors:  R H Gelber
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

2.  Reactions following completion of 1 and 2 year multidrug therapy (MDT).

Authors:  Ma Victoria F Balagon; Robert H Gelber; Rodolfo M Abalos; Roland V Cellona
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

3.  High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks.

Authors:  B Ji; P Jamet; S Sow; E G Perani; I Traore; J H Grosset
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Reverse transcription-PCR detection of Mycobacterium leprae in clinical specimens.

Authors:  M Kurabachew; A Wondimu; J J Ryon
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

Review 5.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

6.  Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice.

Authors:  B Ji; E G Perani; C Petinom; J H Grosset
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Powerful bactericidal activity of moxifloxacin in human leprosy.

Authors:  Fe Eleanor F Pardillo; Jasmin Burgos; Tranquilino T Fajardo; Eduardo Dela Cruz; Rodolfo M Abalos; Rose Maria D Paredes; Cora Evelyn S Andaya; Robert H Gelber
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

8.  Alternate Anti-Leprosy Regimen for Multidrug Therapy Refractory Leprosy: A Retrospective Study from a Tertiary Care Center in North India.

Authors:  Tarun Narang; Anuradha Bishnoi; Sunil Dogra; Uma Nahar Saikia
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

9.  Patterns and determinants of treatment completion and default among newly diagnosed multibacillary leprosy patients: A retrospective cohort study.

Authors:  Veincent Christian F Pepito; Arianna Maever L Amit; Rae Erica D Samontina; Sarah Jane A Abdon; David Norman L Fuentes; Ofelia P Saniel
Journal:  Heliyon       Date:  2021-06-11

10.  Fixed-duration therapy in leprosy: limitations and opportunities.

Authors:  Munisamy Malathi; Devinder Mohan Thappa
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.